The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

WASHINGTON — Medicare officials announced plans to negotiate the prices of blockbuster diabetes and weight loss drugs Ozempic and Wegovy, further complicating big decisions the Trump administration will have to make about how to cover the medications.

List of drugs account for $41 billion in annual Medicare spending, the Biden administration said.

The Biden administration on Friday released the next round of prescription drugs selected for Medicare price negotiations, including Ozempic — the blockbuster diabetes drug that’s also used for weight loss.